China Biologic Products (CBPO)
China Biologic Products Profit Margin: 13.00%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CBPO Profit Margin Rankings
| Overall | 77th percentile | 990 of 4391 |
| Sector | 81st percentile | 88 of 469 in Healthcare |
| Industry | 82nd percentile | 23 of 132 in Biotechnology |
CBPO Profit Margin Range, Past 5 Years
| Minimum | -22.91% | Sep 2009 |
| Maximum | 39.84% | Jun 2011 |
| Average | 15.78% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these CBPO related companies
CBPO News
China Biologic Products Reports Higher Results for the First Quarter 2012
May 08, 4:35PM PR Newswire
May 08, 4:35PM PR Newswire
China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
May 07, 7:10AM PR Newswire
May 07, 7:10AM PR Newswire
China Biologic Has Announced the Resignation of CFO Y. Tristan Kuo and Named Mr. Ming Yang as Interim CFO
Apr 27, 4:30PM PR Newswire
Apr 27, 4:30PM PR Newswire
China Biologic's Board Has Appointed Two New Independent Directors to Boost Corporate Governance
Apr 25, 6:38AM Benzinga
Apr 25, 6:38AM Benzinga
China Biologic (CBPO) Gets Approval from China SFDA to Begin Fibrinogen Trials
Mar 23, 7:26AM Street Insider
Mar 23, 7:26AM Street Insider
China Biologic Receives SFDA Approval to Begin Clinical Trials for Human Fibrinogen
Mar 23, 6:45AM Benzinga
Mar 23, 6:45AM Benzinga
China Biologic to Host Earnings Conference Call on March 13, 2012 at 8:00 a.m. EDT (NY)
Mar 09, 4:15PM PR Newswire
Mar 09, 4:15PM PR Newswire
China Nuokang Bio-Pharmaceutical Inc. Appoints David Gao to Board of Directors
Dec 20, 9:00AM GlobeNewswire
Dec 20, 9:00AM GlobeNewswire
$CBPO Insider Buy: $2.9M of stock bought by Warburg Pincus Partners LLC (Director) on December 16, 2011 http://stks.co/1bxf
about 161 days ago by MarketBrief
about 161 days ago by MarketBrief
$CBPO Insider Buy: $2.9M of stock bought between December 14, 2011 - December 15, 2011 http://stks.co/1aVx
about 164 days ago by MarketBrief
about 164 days ago by MarketBrief
$CBPO Insider Buy: $907K of stock bought between December 12, 2011 - December 13, 2011 http://stks.co/1YAl
about 166 days ago by MarketBrief
about 166 days ago by MarketBrief
$CBPO Insider Buy: $623K of stock bought between December 7, 2011 - December 8, 2011 http://stks.co/1Vka
about 167 days ago by MarketBrief
about 167 days ago by MarketBrief
$CBPO Insider Buy: $572K of stock bought by Warburg Pincus Partners LLC (Director) on December 9, 2011 http://stks.co/1VUd
about 168 days ago by MarketBrief
about 168 days ago by MarketBrief
$CBPO Insider Buy: $623K of stock bought between December 7, 2011 - December 8, 2011 http://stks.co/1Tan
about 171 days ago by MarketBrief
about 171 days ago by MarketBrief
$CBPO Insider Buy: $327K of stock bought between November 29, 2011 - November 30, 2011 http://stks.co/1TQs
about 171 days ago by MarketBrief
about 171 days ago by MarketBrief
$CBPO Insider Buy: $327K of stock bought between November 29, 2011 - November 30, 2011 http://stks.co/1RP8
about 172 days ago by MarketBrief
about 172 days ago by MarketBrief
$CBPO Insider Buy: $1M of stock bought by Warburg Pincus Partners LLC (Director) on December 5, 2011 http://stks.co/1QxZ
about 173 days ago by MarketBrief
about 173 days ago by MarketBrief
$CBPO Insider Buy: $327K of stock bought between November 29, 2011 - November 30, 2011 http://stks.co/1Q3D
about 173 days ago by MarketBrief
about 173 days ago by MarketBrief
$CBPO Insider Buy: $327K of stock bought between November 29, 2011 - November 30, 2011 http://stks.co/1Ore
about 174 days ago by MarketBrief
about 174 days ago by MarketBrief
$CBPO Insider Buy: $327K of stock bought between November 29, 2011 - November 30, 2011 http://stks.co/1NeI
about 175 days ago by MarketBrief
about 175 days ago by MarketBrief
$CBPO Insider Buy: $327K of stock bought between November 29, 2011 - November 30, 2011 http://stks.co/1MsO
about 178 days ago by MarketBrief
about 178 days ago by MarketBrief
$CBPO Insider Buy: $327K of stock bought between November 29, 2011 - November 30, 2011 http://stks.co/1LgG
about 179 days ago by MarketBrief
about 179 days ago by MarketBrief
$CBPO $15.33 Shao Sean director S 5,995 @ $14.08 amnt $84,409 proc'd ($7,494) 5/18/2011
about 369 days ago by canarionyc
about 369 days ago by canarionyc
=> $CBPO $15.33 LANDY JOSEPH P 34,899 @ $14.87 amnt $518,919 proc'd $15,996 5/20/2011
about 369 days ago by canarionyc
about 369 days ago by canarionyc
$CBPO http://chart.ly/blkb8ip Chinese biotech broke out today, could be good for a trade
about 369 days ago by mhass33
about 369 days ago by mhass33
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBPO | 7.90 | -0.03 | -0.38% | 202.24M |
| CBP | 0.56 | +0.01 | +1.82% | 20.85M |
| CBOU | 11.61 | +0.25 | +2.20% | 243.23M |
| CBOE | 25.24 | -0.15 | -0.59% | 2.241B |
| CBNJ | 8.19 | -0.03 | -0.36% | 109.01M |
| CBMX | 0.92 | -0.04 | -4.17% | 9.844M |
| CBM | 7.08 | +0.00 | +0.00% | 209.71M |
| BRS | 43.38 | -0.33 | -0.76% | 1.548B |
| BRO | 25.69 | -0.17 | -0.66% | 3.683B |
| BRN | 3.25 | +0.00 | +0.00% | 26.91M |
